China Universal Asset Management Co. Ltd. Buys 5,707 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

China Universal Asset Management Co. Ltd. boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 99.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,460 shares of the company’s stock after purchasing an additional 5,707 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Structure Therapeutics were worth $503,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $39,000. Quarry LP bought a new position in Structure Therapeutics in the second quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after acquiring an additional 1,420 shares during the period. Bank Pictet & Cie Europe AG bought a new stake in shares of Structure Therapeutics during the third quarter valued at approximately $206,000. Finally, Mather Group LLC. acquired a new position in shares of Structure Therapeutics during the second quarter worth approximately $214,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. JMP Securities reduced their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Price Performance

GPCR opened at $37.86 on Thursday. Structure Therapeutics Inc. has a 1 year low of $26.61 and a 1 year high of $75.02. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -49.17 and a beta of -3.53. The firm’s fifty day moving average price is $39.50 and its two-hundred day moving average price is $39.73.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, equities analysts anticipate that Structure Therapeutics Inc. will post -0.79 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.